EUCTR2014-001673-14-GB进行中（未招募）1 期
ong Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy - CD19 CART Long Term Follow Up (LTFU) study
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients must have received CAR-T therapy within one of the following:
- •Novartis or Penn sponsored CAR-T treatment trials where CAR-T was given as monotherapy or as combination therapy.
- •Novartis managed access programs outside of the commercial setting, i.e. where CAR-T therapy was intended to be given in the setting of a Novartis or Penn sponsored CAR-T treatment trial
- •2.Patients must provide informed consent prior to their entry into this study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 255
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 340
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 105
排除标准
- •- There are no specific exclusion criteria for this study.
研究者
相似试验
招募中
Unknown
CAR-T Long Term Follow Up StudyAny patients have received a Novartis or Penn CAR-T therapyJPRN-jRCT1080225004ovartis Pharma. K.K.14
进行中（未招募）
1 期
ong term follow-up study for patients who have been treated with lentivirus-based chimeric antigen receptor (CAR) T-Cell TherapyAll patients who have been treated with chimeric antigen receptor (CAR) T-cell therapy in the context of a prior Novartis sponsored or supported study for any indication.MedDRA version: 21.0Level: PTClassification code 10003917Term: B-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10003899Term: B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001673-14-SEovartis Pharma Services AG900
进行中（未招募）
1 期
ong term follow-up study for patients who have been treated with lentivirus-based chimeric antigen receptor (CAR) T-Cell TherapyEUCTR2014-001673-14-ITOVARTIS PHARMA SERVICES AG700
进行中（未招募）
1 期
ong term follow-up study for patients who have been treated withlentivirus-based chimeric antigen receptor (CAR) T-Cell TherapyAll patients who have been treated with chimeric antigen receptor (CAR)T-cell therapy in the context of a prior Novartis sponsored or supportedstudy for any indication.MedDRA version: 21.0Level: PTClassification code 10003917Term: B-cell type acute leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10003899Term: B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001673-14-ATovartis Pharma Services AG900
进行中（未招募）
1 期
ong term follow-up study for patients who have been treated with lentivirus-based chimeric antigen receptor (CAR) T-Cell TherapyEUCTR2014-001673-14-BEovartis Pharma Services AG700